Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Gross Margin (2020 - 2025)

Historic Gross Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 52.69%.

  • Cytek Biosciences' Gross Margin fell 36300.0% to 52.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.46%, marking a year-over-year decrease of 14600.0%. This contributed to the annual value of 55.43% for FY2024, which is 12700.0% down from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Gross Margin is 52.69%, which was down 36300.0% from 52.34% recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Gross Margin peaked at 66.36% during Q3 2022, and registered a low of 48.62% during Q1 2025.
  • Moreover, its 5-year median value for Gross Margin was 56.75% (2023), whereas its average is 57.59%.
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 217200bps in 2021, then tumbled by -97400bps in 2023.
  • Over the past 5 years, Cytek Biosciences' Gross Margin (Quarter) stood at 60.77% in 2021, then rose by 0bps to 60.77% in 2022, then fell by -7bps to 56.75% in 2023, then grew by 3bps to 58.55% in 2024, then fell by -10bps to 52.69% in 2025.
  • Its last three reported values are 52.69% in Q3 2025, 52.34% for Q2 2025, and 48.62% during Q1 2025.